What is HC Wainwright’s Forecast for CMPX FY2025 Earnings?

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Equities research analysts at HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for Compass Therapeutics in a research report issued to clients and investors on Monday, November 10th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($0.42) for the year, up from their previous forecast of ($0.55). The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Compass Therapeutics’ Q4 2025 earnings at ($0.14) EPS.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.06.

Other analysts also recently issued research reports about the stock. D. Boral Capital reissued a “buy” rating and set a $30.00 price target on shares of Compass Therapeutics in a research report on Wednesday, November 5th. Lifesci Capital initiated coverage on shares of Compass Therapeutics in a research note on Monday, October 6th. They set an “outperform” rating and a $10.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Compass Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Compass Point set a $10.00 price target on Compass Therapeutics in a research note on Monday, October 6th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Compass Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.90.

Compass Therapeutics Stock Up 8.2%

CMPX stock opened at $4.63 on Wednesday. Compass Therapeutics has a 52-week low of $1.27 and a 52-week high of $4.86. The stock’s 50 day moving average is $3.82 and its two-hundred day moving average is $3.02. The company has a market capitalization of $640.24 million, a PE ratio of -10.29 and a beta of 1.48.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Creative Planning acquired a new stake in Compass Therapeutics in the second quarter worth $30,000. Strs Ohio bought a new position in shares of Compass Therapeutics during the first quarter worth about $34,000. Apollon Wealth Management LLC acquired a new stake in shares of Compass Therapeutics in the 3rd quarter worth about $35,000. Birchview Capital LP bought a new stake in Compass Therapeutics in the 1st quarter valued at about $46,000. Finally, Walleye Trading LLC acquired a new position in Compass Therapeutics during the 1st quarter valued at about $48,000. 68.43% of the stock is currently owned by institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.